Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home

User menu

  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

ASHNR American Society of Functional Neuroradiology ASHNR American Society of Pediatric Neuroradiology ASSR
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

AJNR Awards, New Junior Editors, and more. Read the latest AJNR updates

Research ArticleNeurointervention

Feasibility and Safety of Repeat Instant Endovascular Interventions in Patients with Refractory Cerebral Vasospasms

L. Andereggen, J. Beck, W.J. Z'Graggen, G. Schroth, R.H. Andres, M. Murek, M. Haenggi, M. Reinert, A. Raabe and J. Gralla
American Journal of Neuroradiology March 2017, 38 (3) 561-567; DOI: https://doi.org/10.3174/ajnr.A5024
L. Andereggen
aFrom the Department of Neurosurgery (L.A., J.B., W.J.Z., R.H.A., M.M., M.R., A.R.)
bInstitute for Diagnostic and Interventional Neuroradiology (L.A., G.S., J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for L. Andereggen
J. Beck
aFrom the Department of Neurosurgery (L.A., J.B., W.J.Z., R.H.A., M.M., M.R., A.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J. Beck
W.J. Z'Graggen
aFrom the Department of Neurosurgery (L.A., J.B., W.J.Z., R.H.A., M.M., M.R., A.R.)
cDepartments of Neurology (W.J.Z.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for W.J. Z'Graggen
G. Schroth
bInstitute for Diagnostic and Interventional Neuroradiology (L.A., G.S., J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for G. Schroth
R.H. Andres
aFrom the Department of Neurosurgery (L.A., J.B., W.J.Z., R.H.A., M.M., M.R., A.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for R.H. Andres
M. Murek
aFrom the Department of Neurosurgery (L.A., J.B., W.J.Z., R.H.A., M.M., M.R., A.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Murek
M. Haenggi
dIntensive Care Medicine (M.H.), Inselspital, Bern University Hospital, University of Bern, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Haenggi
M. Reinert
aFrom the Department of Neurosurgery (L.A., J.B., W.J.Z., R.H.A., M.M., M.R., A.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Reinert
A. Raabe
aFrom the Department of Neurosurgery (L.A., J.B., W.J.Z., R.H.A., M.M., M.R., A.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A. Raabe
J. Gralla
bInstitute for Diagnostic and Interventional Neuroradiology (L.A., G.S., J.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J. Gralla
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Responses
  • References
  • PDF
Loading

Abstract

BACKGROUND AND PURPOSE: For patients with cerebral vasospasm refractory to medical and hemodynamic therapies, endovascular therapies often remain the last resort. Data from studies in large cohorts on the efficacy and safety of multiple immediate endovascular interventions are sparse. Our aim was to assess the feasibility and safety of multiple repeat instant endovascular interventions in patients with cerebral vasospasm refractory to medical, hemodynamic, and initial endovascular interventions.

MATERIALS AND METHODS: This was a single-center retrospective study of prospectively collected data on patients with cerebral vasospasm refractory to therapies requiring ≥3 endovascular interventions during the course of treatment following aneurysmal subarachnoid hemorrhage. The primary end point was functional outcome at last follow-up (mRS ≤2). The secondary end point was angiographic response to endovascular therapies and the appearance of cerebral infarctions.

RESULTS: During a 4-year period, 365 patients with aneurysmal subarachnoid hemorrhage were treated at our institution. Thirty-one (8.5%) met the inclusion criteria. In 52 (14%) patients, ≤2 endovascular interventions were performed as rescue therapy for refractory cerebral vasospasm. At last follow-up, a good outcome was noted in 18 (58%) patients with ≥3 interventions compared with 31 (61%) of those with ≤2 interventions (P = .82). The initial Hunt and Hess score of ≤2 was a significant independent predictor of good outcome (OR, 4.7; 95% CI, 1.2–18.5; P = .03), whereas infarcts in eloquent brain areas were significantly associated with a poor outcome (mRS 3–6; OR, 13.5; 95% CI, 2.3–81.2; P = .004).

CONCLUSIONS: Repeat instant endovascular intervention is an aggressive but feasible last resort treatment strategy with a favorable outcome in two-thirds of patients with refractory cerebral vasospasm and in whom endovascular treatment has already been initiated.

ABBREVIATIONS:

CVS
cerebrovascular vasospasm
GCS
Glasgow Coma Scale
HH
Hunt and Hess
IAN
intra-arterial nimodipine
PTA
percutaneous transluminal balloon angioplasty
RCVS
refractory CVS

Cerebral vasospasm (CVS) after aneurysmal subarachnoid hemorrhage remains a major cause of delayed cerebral ischemia and related morbidity and mortality.1,2 Standard treatment consists of hyperdynamic/hypertensive therapy and orally administered nimodipine to prevent ischemic events.3,4 Nevertheless, 20%–30% of patients develop refractory CVS with cerebral infarction causing permanent neurologic deficits or death.5 In cases of severe CVS and threatened ischemia despite hemodynamic and medical treatment, no commonly accepted treatment guidelines exist.6 Although endovascular methods offer some last resort treatment options, their use is generally not extended throughout the entire CVS course and application is limited to 1 or 2 or, at most, 3 interventions, resulting in an ambiguous functional outcome with most patients unable to resume work post-SAH.7⇓⇓–10

In this single-center audit of practice, we evaluated repeat immediate endovascular therapies in a subgroup of symptomatic patients with the most severe, refractory CVS during the vasospasm period.

Materials and Methods

Patient Inclusion Criteria and Study End Points

To comply with the inclusion criteria, patients with proved aneurysmal subarachnoid hemorrhage had to fulfill the requirement of medically and hemodynamic refractory CVS (rCVS) necessitating ≥3 endovascular interventions during the CVS period. These patients were compared with a cohort of patients with aneurysmal subarachnoid hemorrhage necessitating 1–2 endovascular interventions during the refractory CVS period. Patients with mycotic aneurysms were excluded from the study. The primary end point was functional outcome at last follow-up (modified Rankin Scale ≤2). The secondary end point was angiographic response to endovascular therapies and the appearance of cerebral infarctions.

Management of CVS

After early aneurysm treatment (≤24 hours with either clip or coil embolization), patients were continuously monitored in the intensive care unit and kept normovolemic with blood pressure at normal high levels. A daily check was made of electrolytes (ie, sodium), and an assessment with transcranial Doppler was performed. Medical therapy consisted of nimodipine administered by the enteral route (60 mg every 4 hours for 21 days). In conscious patients, immediate endovascular therapy was indicated in cases of symptomatic rCVS, defined as the appearance of a new neurologic deficit despite medical and hemodynamic treatment (ie, hyperdynamic/hypertensive therapy) or a decline in consciousness not resulting from hydrocephalus (ie, an NIHSS score increase of ≥2 and/or a Glasgow Coma Scale [GCS] score decrease of ≥2). In unconscious patients, rising transcranial Doppler mean velocities of ≥150 cm/s or increased flow velocity of ≥50 cm/s during 24 hours was considered an indication for endovascular treatment in cases in which the CT perfusion scan or MR imaging showed a mean transit time of >5.9 seconds.11 Other indications for endovascular rescue therapies included patients with marked changes in brain-tissue oxygen pressure values (<15 mm Hg, Licox Brain Oxygen Monitoring System [Integra LifeSciences, Saint Priest, France]) who were not responding to medical and hemodynamic therapies when the MR imaging showed a diffusion-perfusion mismatch.12,13

Endovascular Interventions

Intra-arterial nimodipine (IAN) with continuous infusion was delivered locally through a 0.18-inch microcatheter (Renegade Hi-Flo; Boston Scientific, Natick, Massachusetts) into the most affected intracranial vessel segments. A dose of 2.5 mg of nimodipine was administered at the most proximal site of each spastic artery (12 mL in 38-mL saline, administered at 20–30 mL per hour for 30 minutes). Repeat angiography was performed 30 minutes after IAN to evaluate the response of the spastic vessels. In cases of poor response to IAN, percutaneous transluminal balloon angioplasty (PTA) was performed by using intracranial balloon catheters (Gateway; Stryker, Kalamazoo, Michigan). Balloon diameter and inflation pressure were chosen according to the target vessel diameter before vasospasm. “Angiographic CVS” was defined as narrowing of the arterial diameter by ≥30% from the baseline diameter, as assessed by 2 experienced interventional neuroradiologists (G.S., J.G.).

Neurologic Outcome

The immediate response to IAN and/or PTA was evaluated by neurosurgeons and critical care physicians. In those patients who did not respond, MR imaging was performed. In cases of confirmed multiple ischemic areas without any salvageable penumbra, therapy was suspended.14,15 Complications resulting from SAH, obliteration procedures, and multiple interventions were recorded separately according to the clinical protocol. Neurologic outcome was assessed by mRS, the GCS, and Glasgow Outcome Scale at discharge and at the last follow-up.5 For patients who lacked long-term follow-up data, the mRS was assessed via telephone interview.16 The patients' morbidity and reintegration into the workplace at last follow-up were documented.

Assessment of Stroke

Radiologic ischemia was documented with CT or MR imaging.17 Twenty-four hours following radiologic or surgical aneurysm obliteration, a cerebral CT scan was obtained in all patients to look for treatment-related ischemia. CT scans or MR imaging at the time of patient discharge allowed the visualization of new stroke areas resulting from CVS during the clinical course. Associated functional deficits were registered.

Statistical Methods

Data were analyzed by using SPSS statistical software, Version 21.0 (IBM, Armonk, New York). Clinical outcome was dichotomized into favorable (mRS ≤2) and poor outcome (mRS ≥3). Data are given as mean ± SD unless otherwise stated. For comparisons of means between the 2 analysis groups (ie, <2 interventions versus ≥3 interventions), the Student t test was used for normally distributed data (comparing patient age and follow-up time), and the Mann-Whitney U test, for skewed or non-normal data (comparing the number of treatments, vessel segments treated, and vascular territories). The other categoric variables were compared between the 2 analysis groups by using the Pearson χ2 test or the Fisher exact test, as appropriate (Tables 1 and 2). To identify predictors of good functional outcome (mRS ≤2), we performed multivariable analysis with a binary logistic regression model, including the following variables: patient age, sex, Hunt and Hess (HH) grade after SAH, the number of treatments, the number of vessels treated, the number of vascular territories, aneurysm location, further aneurysms, aneurysm obliteration, necessity for PTA, cerebral infarcts, and length of follow-up. Odds ratios and 95% CI were calculated. P values ≤ .05 were considered statistically significant.

View this table:
  • View inline
  • View popup
Table 1:

Characteristics of patients with cerebral vasospasm treated with ≥3 interventions compared with those treated with ≤2 interventions

View this table:
  • View inline
  • View popup
Table 2:

Primary and secondary outcome measurements following multiple interventions

Results

Patient Demographics

During the 4-year study period, 365 patients with aneurysmal SAH were admitted to our institution. Thirty-one (8.5%) met the inclusion criteria with ≥3 endovascular interventions during the CVS period. In 52 patients with aneurysmal SAH, 1–2 endovascular interventions were performed during the CVS period. Patient characteristics did not differ significantly between the 2 cohorts and are summarized in Table 1 (see also On-line Table 1). Mean age was 54 years (range, 24–77 years), and 66 (80%) were women. Forty-five (54%) patients presented with a Hunt and Hess grade of ≥3.18 At admission, a mild GCS score of 14–15 was noted in 42% of patients; a moderate score (GCS, 9–13), in 21%; and a severe score (GCS, 3–8), in 38%. Most patients (92%) presented with a Fisher grade 319 at clinical onset. Patients with aneurysms not suitable for coil embolization were treated with clip reconstruction (29% of patients) based on interdisciplinary review. Thirty-six percent of patients presented with multiple aneurysms. In 65% of patients, the ruptured aneurysm was located in the anterior, and in 35%, in the posterior circulation. In 51 patients (63%), an external ventricular drain was inserted due to acute hydrocephalus.

Endovascular Interventions

The number of treatments, vessel segments treated, and vascular territories and the requirement for PTA were significantly higher in patients with ≥3 interventions than in patients with ≤2 interventions (Table 1). Endovascular treatment for CVS was performed between 3 and 15 days after the initial ictus (mean, 6 days). The mean clinical course of vasospasm lasted for 4.8 ± 2.8 days (range, 1–14 days); in 15 patients (48%), it lasted for >5 days. A total of 210 (mean, 2.5 ± 1.7 per patient) endovascular interventions were performed (mean, 4.3 ± 1.6 in patients with ≥3 interventions, versus mean, 1.5 ± 0.5 in patients with ≤2 interventions; P < .001), resulting in the treatment of 450 vessel segments (mean, 5.4 ± 5.3 per patient; range, 1–40 segments; mean, 9.6 ± 6.6 in patients with ≥3 interventions, versus mean, 2.9 ± 1.5 in patients with ≤2 interventions; P < .001), and 157 vascular territories (mean, 1.9 ± 0.8 per patient; range, 1–3; mean, 2.3 ± 0.8 in patients with ≥3 interventions, versus mean, 1.6 ± 0.7 in patients with ≤2 interventions; P < .001). A moderate immediate angiographic effect (arterial dilation <30%) was observed after IAN in 26 (31%) interventions, and consecutive transluminal PTA was applied in these cases, namely in 9 (17%) patients with ≤2 interventions versus 17 (55%) patients with ≥3 interventions (P = .001). In the cohort of patients with ≥3 interventions, 13 (42%) underwent 3 treatment sessions, 8 (26%) underwent 4 sessions, 4 (13%) underwent 5 sessions, and 4 (13%) underwent 6 sessions (Fig 1). One patient had a total of 7 treatment sessions, and another, 10 sessions during the CVS course. Of the 52 patients with ≤2 interventions, 26 (50%) underwent 1 treatment session and 26 (50%), 2 sessions.

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Repeat angiograms in refractory cerebral vasospasms. Repeat angiograms (red arrows: proximal spastic vessels; blue arrows: distal spastic vessels) in a 41-year-old woman with a ruptured anterior communicating artery aneurysm initially treated with coil embolization. On day 8 after the ictus, the patient presented with hemiparesis on the left side. A, ICA angiogram, anteroposterior view, shows vasospasm of the right-sided M1 and A1/A2 segments. B, ICA angiogram of the same patient after nimodipine infusion demonstrates reduced vasospasm of the M1 and A1/A2 segments, with improved perfusion of both the proximal and distal arteries. C–M, Corresponding angiograms of the anterior circulation (C, D, G, H, L, M) and posterior circulation (E, F, I, K) in the same patient during the CVS period from day 9 to day 13. Images on the right side show the effect after IAN. Note the effect of nimodipine infusion on the vessel diameter (white arrows).

Functional Outcome

Functional outcome was recorded at discharge (mean, 3 weeks; range, 2–6 weeks) and after a median follow-up at 10 months (range, 1–24 months; Table 2 and On-line Table 2). A good functional outcome (median mRS ≤2) at last follow-up was recorded in 49 patients (60%); a poor outcome (median mRS 3–6), in 33 patients (40%), with no statistically significant difference between the 2 cohorts (P = .82). Persistent disabilities requiring constant nursing care (mRS 4–5) were noted in 4 patients (8%) with ≤2 interventions and in 3 (10%) of those with ≥3 interventions. Overall mortality (mRS 6) was 20%, with no differences between the 2 cohorts (P = .31).

Sixty-one percent of patients rated headache/fatigue and 39%, a persisting neurologic deficit as the most disturbing long-term effect. In patients with ≥3 interventions, none of the working-age patients were able to work full-time at long-term follow-up, 42% worked part-time either in the same or another profession, 23% had no employment, and early retirement was taken by 3%. In contrast, in patients with ≤2 interventions, 5 (6%) of the working-age patients were able to work full-time, whereas 6 (13%) worked part-time either in the same or another profession. Sixteen (33%) patients had no employment at last follow-up.

The following variable was associated with a good functional outcome (median mRS 0–2) at last follow-up (Table 3): Hunt and Hess scale of ≤2 (OR, 7.6; 95% CI, 2.7–22.3; P <.001), whereas new cerebral infarctions (OR, 14.8; 95% CI, 3.9–55.3; P < .001) and infarction in eloquent areas (OR, 26.0; 95% CI, 7.7–88.2; P < .001) were associated with a poor outcome (median mRS >2). Multivariable analysis revealed the HH scale score of ≤2 (OR, 4.7; 95% CI, 1.2–18.5; P = .03) as an independent predictor of favorable functional outcome (mRS ≤2) and infarcts in eloquent areas (OR, 13.5; 95% CI, 2.3–81.2; P = .004) as an independent risk factor for poor outcome (mRS 3–6) at last follow-up.

View this table:
  • View inline
  • View popup
Table 3:

Factors associated with good functional outcome (mRS ≤2) at last follow-up

Cerebral Infarctions

Assessments of new infarcted areas and infarcts in eloquent regions are shown in Table 2 and On-line Table 2. New infarcted areas at discharge were registered in 23 (74%) patients with ≥3 interventions compared with 26 (52%) patients with ≤2 interventions (P = .06). There was no difference between the 2 cohorts regarding infarcts located in eloquent brain areas, which were observed in 17 (55%) patients with ≥3 interventions versus 18 (37%) patients with ≤2 interventions (P = .17). We identified the following risk factors associated with infarction at discharge (Table 4): number of treatments (OR, 1.4; 95% CI, 1.0–1.9; P = .05), number of vessels treated (OR, 1.2; 95% CI, 1.0–1.4; P = .03), and requirement for PTA (OR, 2.7; 95% CI, 1.0–7.9; P = .06). Multivariable analysis revealed the HH scale score of ≥3 (OR, 3.4; 95% CI, 1.2–9.3; P = .02) and the number of vascular territories treated (OR, 3.1; 95% CI, 1.3–7.3; P = .01) as independent predictors of infarcts at discharge.

View this table:
  • View inline
  • View popup
Table 4:

Risk factors associated with infarction at discharge

Treatment-Related Morbidity and Mortality

There was no treatment-related mortality. Complications resulting from aneurysm obliteration procedures consisted of 2 (2%) patients with thrombosis of the parent vessel during coil embolization, which dissolved following intra-arterial thrombolytic therapy. In 1 patient (1%), aneurysm rerupture during coil embolization occurred but did not result in a clinical decline.

Complications resulting from spasmolysis therapies consisted of dissection in the access vessel of the ICA in 1 (2%) patient with ≤2 interventions versus 5 (16%) patients with ≥3 interventions (P = .03), requiring stent placement for persistent high-grade stenosis in 1 patient. Another patient (1%) developed a pseudoaneurysm at the puncture side of the femoral artery.

Discussion

IAN offers some last resort treatment strategies, yet application generally remains limited to 1 or 2 or, at most, 3 interventions.20⇓⇓–23 Cases of patients undergoing >3 endovascular interventions in response to persistent, recurrent, or worsening CVS have seldom been described, and results on functional outcome remain ambiguous.24 Jun et al25 reported a subgroup of patients (6%, 12 of 189) with rCVS who underwent ≥3 endovascular interventions, and Pandey et al, 26 a subgroup of 7% of patients (2 of 27); but no functional outcome was reported in this subgroup of patients. Most interesting, in the study by Pandey et al, nicardipine was infused through a cervical catheter, with selective catheterization and angioplasty reserved for refractory cases, thereby reducing the risk related to microcatheterization itself.26 In their series, no complications attributed to the angiographic interventions were described. Given that the rate of cervical artery dissections was higher than that recorded in other studies,25,27 less aggressive approaches might be considered in selected cases.

Due to the transient vasodilatory effects of IAN,23,28⇓⇓–31 Albanese et al7 reported prevention of new ischemic events in 9 of 12 patients with prolonged intra-arterial infusion of verapamil. However, catheterization over an extended period might increase the risk of thrombus formation and subsequent embolisms.29 Additionally, it generally involves different personnel in the intensive care unit, thereby increasing the risk of air embolism by manipulating the perfusion system. Indeed, repeat endovascular procedures via microcatheterization had greater risks for related complications but also allowed immediate initiation of endovascular therapies, which has been shown to markedly improve outcome compared with patients whose treatment was delayed.32

Depending on the location and severity of the CVS, either PTA or IAN can be used in the clinical setting. Balloon angioplasty is indeed effective in treating proximal artery vasospasms and results in more durable clinical improvement.25,33,34 However, in smaller and more distal vessels, this technique is limited by the possibility of vessel rupture.27 For more distal or diffuse vasospasms with reduced parenchymal perfusion, several superselective intra-arterial agents have been shown to be effective though transient.35 A number of clinical studies regarding the effect of intra-arterial nimodipine in patients with severe refractory CVS exist8,9,36; however, some controversy remains as to the effectiveness of IAN.37 Furthermore, these reports comprise mostly small, retrospective case series.38

While we noted a good clinical outcome in 61% of patients with ≤2 interventions versus 58% with ≥3 interventions (P = .82) after a median follow-up of 10 ± 8 months, 70% of patients recruited for the Barrow Ruptured Aneurysm Trial (BRAT) showed good functional outcome after 1 year,39 67% after 3 years,40 and 62% after 6 years following SAH.41

In patients recruited for the International Subarachnoid Aneurysm Trial (ISAT), an mRS of ≤2 after 1 year was reported in 72.8% of them and in 70.2% 8 years later.42⇓–44 However, the BRAT and ISAT trials represent the full range of patients, including those with a good-grade SAH,45 thus not reflecting the subpopulation at highest risk for refractory CVS with subsequent infarction and poor quality of life.46

Most important, a poor neurologic outcome (mRS 4 or 5) with persistent disabilities requiring constant nursing care could be prevented in most patients. Pegoli et al46 noted an excellent outcome (mRS 0–1) in 63% of patients with aneurysmal SAH; however, symptomatic CVS and consecutive infarctions were risk factors for poor outcome.46,47

As many as 91% of patients with poor quality of life following SAH failed to return to full-time work.48 Aneurysmal SAH is a cerebrovascular disease particularly affecting the younger working-age population, thereby increasing the economic burden for numerous patients, their families, and society as a whole.49,50 At last follow-up, only 6% of patients worked full-time, 24% of patients worked part-time, and 29% were unemployed. Our results are in line with these earlier findings. Indeed, vasospasm-related delayed ischemic neurologic deficits and cerebral infarction are strongly associated with unfavorable outcomes following SAH.15,51,52 While cerebral or angiographic vasospasm is a treatable condition, the effectiveness of nimodipine, hemodynamic therapy, and endovascular interventions, including angioplasty, in preventing neurologic deficits remains controversial.53⇓–55

In summary, our approach of immediate repeat endovascular interventions in patients with the most severe CVS refractory to traditional therapies resulted in a favorable outcome in about two-thirds of patients and prevented severe disability in most of them. However, it remains difficult to assess whether immediate endovascular treatments ultimately result in a better neurologic outcome because vasospasm is not the only cause of delayed ischemic complications.56

Nevertheless, rescue therapies to reduce the impact of rCVS following SAH might be beneficial in devastating cases. On the basis of the current data and from the experience we gained from performing these procedures in this subpopulation of patients at highest risk for refractory CVS, we think that it is important to continue the effort to treat even those patients who are refractory to 1 or 2 endovascular interventions, even when little or no effect and ongoing cerebral vasospasm are evident. Large multicenter, prospective, randomized controlled studies are, however, needed to prove the effectiveness of repeat instant endovascular interventions in patients with refractory cerebral vasospasms—not an easy undertaking given the ethical problems of withholding therapeutic interventions, even if the effect of the therapy remains ambiguous. At present, treatment of rCVS with immediate multiple endovascular interventions is feasible and safe and may be warranted until the significance of these interventions becomes better understood.

Study Limitations

Assessment of cerebral infarctions by CT in 36% of all patients may actually lower the true rate of radiographically detected cerebral infarctions, given the higher sensitivity of MR imaging in detecting vasospasm-related infarction.17 In addition, a median follow-up of 10 ± 7.0 months may under-represent the true rate of poor outcome, considering longer term outcome studies that showed a steady increase in patients with poor outcome across time.39,41

Conclusions

The use of immediate repeat endovascular interventions is an aggressive but feasible last resort treatment strategy effective for a selected subgroup of patients who fail to respond to traditional CVS therapies and endovascular interventions.

Acknowledgments

The assistance of Ms Susan Kaplan in preparing this manuscript is acknowledged. We wish to thank Dr Corrado Bernasconi for statistical advice.

Footnotes

  • Disclosures: Lukas Andereggen—UNRELATED: Grants/Grants Pending: Swiss National Science Foundation. Werner Z'Graggen—UNRELATED: Employment: Bern University Hospital. Gerhard Schroth—UNRELATED: Employment: Bern University Hospital, Comments: normal salary as a 50% senior consultant of the University Institute for Diagnostic and Interventional Neuroradiology of Bern University Hospital Inselspital; Grants/Grants Pending: Swiss National Science Foundation, Comments: grant for neuropsychological investigations before and after carotid stenting*; Payment for Lectures including Service on Speakers Bureaus: European Stroke Organisation, Master Course at the Danube University in Krems, Austria, Comments: lectures and hands-on workshops; money paid exclusively to the Inselspital. Michael Reinert—UNRELATED: Consultancy: Brainlab, DePuys Synthes*; Employment: Ente Ospedaliero Cantonale Ticino; Grants/Grants Pending: Lega Ticinesi contro il Cancro*; Payment for Lectures including Service on Speakers Bureaus: Brainlab.* Jan Gralla—UNRELATED: Consultancy: Covidien, Comments: former Global Principal Investigator for the Star Study on thrombectomy in acute stroke, consultant for Covidien.* *Money paid to the institution.

  • The authors declare no conflict of interest. This study was approved by the Ethics Committee of the Canton of Bern, Switzerland (Kantonale Ethikkommission Bern, KEK, 177/14).

  • Paper previously presented in part at: Vasospasm 2013: The 13th International Conference on Neurovascular Events after Subarachnoid Hemorrhage, Lucerne, Switzerland; July 10–12, 2013.

References

  1. 1.↵
    1. Naidech AM,
    2. Drescher J,
    3. Tamul P, et al
    . Acute physiological derangement is associated with early radiographic cerebral infarction after subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2006;77:1340–44 doi:10.1136/jnnp.2006.089748 pmid:16820419
    Abstract/FREE Full Text
  2. 2.↵
    1. van Gijn J,
    2. Kerr RS,
    3. Rinkel GJ
    . Subarachnoid haemorrhage. Lancet 2007;369:306–18 doi:10.1016/S0140-6736(07)60153-6 pmid:17258671
    CrossRefPubMed
  3. 3.↵
    1. Kassell NF,
    2. Sasaki T,
    3. Colohan AR, et al
    . Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 1985;16:562–72 doi:10.1161/01.STR.16.4.562 pmid:3895589
    Abstract/FREE Full Text
  4. 4.↵
    1. Platz J,
    2. Guresir E,
    3. Vatter H, et al
    . Unsecured intracranial aneurysms and induced hypertension in cerebral vasospasm: is induced hypertension safe? Neurocrit Care 2011;14:168–75 doi:10.1007/s12028-011-9510-2 pmid:21286853
    CrossRefPubMed
  5. 5.↵
    1. Frontera JA,
    2. Fernandez A,
    3. Schmidt JM, et al
    . Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition? Stroke 2009;40:1963–68 doi:10.1161/STROKEAHA.108.544700 pmid:19359629
    Abstract/FREE Full Text
  6. 6.↵
    1. Kimball MM,
    2. Velat GJ,
    3. Hoh BL
    . Critical care guidelines on the endovascular management of cerebral vasospasm. Neurocrit Care 2011;15:336–41 doi:10.1007/s12028-011-9600-1 pmid:21761272
    CrossRefPubMed
  7. 7.↵
    1. Albanese E,
    2. Russo A,
    3. Quiroga M, et al
    . Ultrahigh-dose intraarterial infusion of verapamil through an indwelling microcatheter for medically refractory severe vasospasm: initial experience—clinical article. J Neurosurg 2010;113:913–22 doi:10.3171/2009.9.JNS0997 pmid:19877802
    CrossRefPubMed
  8. 8.↵
    1. Biondi A,
    2. Ricciardi GK,
    3. Puybasset L, et al
    . Intra-arterial nimodipine for the treatment of symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage: preliminary results. AJNR Am J Neuroradiol 2004;25:1067–76 pmid:15205150
    Abstract/FREE Full Text
  9. 9.↵
    1. Hängg D,
    2. Turowski B,
    3. Beseoglu K, et al
    . Intra-arterial nimodipine for severe cerebral vasospasm after aneurysmal subarachnoid hemorrhage: influence on clinical course and cerebral perfusion. AJNR Am J Neuroradiol 2008;29:1053–60 doi:10.3174/ajnr.A1005 pmid:18372422
    Abstract/FREE Full Text
  10. 10.↵
    1. Komotar RJ,
    2. Zacharia BE,
    3. Otten ML, et al
    . Controversies in the endovascular management of cerebral vasospasm after intracranial aneurysm rupture and future directions for therapeutic approaches. Neurosurgery 2008;62:897–905; discussion 905–897 doi:10.1227/01.neu.0000318175.05591.c3 pmid:18496195
    CrossRefPubMed
  11. 11.↵
    1. Dankbaar JW,
    2. de Rooij NK,
    3. Rijsdijk M, et al
    . Diagnostic threshold values of cerebral perfusion measured with computed tomography for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke 2010;41:1927–32 doi:10.1161/STROKEAHA.109.574392 pmid:20689085
    Abstract/FREE Full Text
  12. 12.↵
    1. Beck J,
    2. Raabe A,
    3. Lanfermann H, et al
    . Tissue at risk concept for endovascular treatment of severe vasospasm after aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2004;75:1779–81 doi:10.1136/jnnp.2004.036921 pmid:15548506
    Abstract/FREE Full Text
  13. 13.↵
    1. Beck J,
    2. Raabe A,
    3. Lanfermann H, et al
    . Effects of balloon angioplasty on perfusion- and diffusion-weighted magnetic resonance imaging results and outcome in patients with cerebral vasospasm. J Neurosurg 2006;105:220–27 doi:10.3171/jns.2006.105.2.220 pmid:17219826
    CrossRefPubMed
  14. 14.↵
    1. Vatter H,
    2. Güresir E,
    3. Berkefeld J, et al
    . Perfusion-diffusion mismatch in MRI to indicate endovascular treatment of cerebral vasospasm after subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2011;82:876–83 doi:10.1136/jnnp.2010.219592 pmid:21436228
    Abstract/FREE Full Text
  15. 15.↵
    1. Vergouwen MD,
    2. Ilodigwe D,
    3. Macdonald RL
    . Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and -independent effects. Stroke 2011;42:924–29 doi:10.1161/STROKEAHA.110.597914 pmid:21311062
    Abstract/FREE Full Text
  16. 16.↵
    1. Janssen PM,
    2. Visser NA,
    3. Dorhout Mees SM, et al
    . Comparison of telephone and face-to-face assessment of the modified Rankin Scale. Cerebrovasc Dis 2010;29:137–39 doi:10.1159/000262309 pmid:19955737
    CrossRefPubMed
  17. 17.↵
    1. Shimoda M,
    2. Takeuchi M,
    3. Tominaga J, et al
    . Asymptomatic versus symptomatic infarcts from vasospasm in patients with subarachnoid hemorrhage: serial magnetic resonance imaging. Neurosurgery 2001;49:1341–48; discussion 1348–50 doi:10.1097/00006123-200112000-00010 pmid:11846933
    CrossRefPubMed
  18. 18.↵
    1. Hunt WE,
    2. Hess RM
    . Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg 1968;28:14–20 doi:10.3171/jns.1968.28.1.0014 pmid:5635959
    CrossRefPubMed
  19. 19.↵
    1. Fisher CM,
    2. Kistler JP,
    3. Davis JM
    . Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980;6:1–9 doi:10.1227/00006123-198001000-00001 pmid:7354892
    CrossRefPubMed
  20. 20.↵
    1. Aburto-Murrieta Y,
    2. Marquez-Romero JM,
    3. Bonifacio-Delgadillo D, et al
    . Endovascular treatment: balloon angioplasty versus nimodipine intra-arterial for medically refractory cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Vasc Endovasc Surg 2012;46:460–65 doi:10.1177/1538574412454585 pmid:22914892
    Abstract/FREE Full Text
  21. 21.↵
    1. John S,
    2. Spiotta AM,
    3. Turner RM, et al
    . Initial experience with the coaxial dual-lumen Scepter C balloon catheter for endovascular management of cerebral vasospasm from subarachnoid hemorrhage. J Neurointerv Surg 2014;6:125–28 doi:10.1136/neurintsurg-2012-010572 pmid:23371937
    Abstract/FREE Full Text
  22. 22.↵
    1. Santillan A,
    2. Knopman J,
    3. Zink W, et al
    . Transluminal balloon angioplasty for symptomatic distal vasospasm refractory to medical therapy in patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 2011;69:95–101; discussion 102 doi:10.1227/NEU.0b013e31821424f9 pmid:21368694
    CrossRefPubMed
  23. 23.↵
    1. Wolf S,
    2. Martin H,
    3. Landscheidt JF, et al
    . Continuous selective intraarterial infusion of nimodipine for therapy of refractory cerebral vasospasm. Neurocrit Care 2010;12:346–51 doi:10.1007/s12028-009-9317-6 pmid:20033353
    CrossRefPubMed
  24. 24.↵
    1. Mortimer AM,
    2. Steinfort B,
    3. Faulder K, et al
    . Institution of sustained endovascular treatment prior to clinical deterioration in patients with severe angiographic vasospasm: A retrospective observational study of clinico-radiological outcomes. J Neuroradiol 2015;42:176–83 doi:10.1016/j.neurad.2014.12.002 pmid:25649394
    CrossRefPubMed
  25. 25.↵
    1. Jun P,
    2. Ko NU,
    3. English JD, et al
    . Endovascular treatment of medically refractory cerebral vasospasm following aneurysmal subarachnoid hemorrhage. AJNR Am J Neuroradiol 2010;31:1911–16 doi:10.3174/ajnr.A2183 pmid:20616179
    Abstract/FREE Full Text
  26. 26.↵
    1. Pandey P,
    2. Steinberg GK,
    3. Dodd R, et al
    . A simplified method for administration of intra-arterial nicardipine for vasospasm with cervical catheter infusion. Neurosurgery 2012;71(1 suppl operative):77–85 doi:10.1227/NEU.0b013e3182426257 pmid:22105209
    CrossRefPubMed
  27. 27.↵
    1. Zwienenberg-Lee M,
    2. Hartman J,
    3. Rudisill N, et al
    ; Balloon Prophylaxis for Aneurysmal Vasospasm (BPAV) Study Group. Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial. Stroke 2008;39:1759–65 doi:10.1161/STROKEAHA.107.502666 pmid:18420953
    Abstract/FREE Full Text
  28. 28.↵
    1. Doukas A,
    2. Petridis AK,
    3. Barth H, et al
    . Resistant vasospasm in subarachnoid hemorrhage treated with continuous intraarterial nimodipine infusion. Acta Neurochir Suppl 2011;112:93–96 doi:10.1007/978-3-7091-0661-7_16 pmid:21691994
    CrossRefPubMed
  29. 29.↵
    1. Musahl C,
    2. Henkes H,
    3. Vajda Z, et al
    . Continuous local intra-arterial nimodipine administration in severe symptomatic vasospasm after subarachnoid hemorrhage. Neurosurgery 2011;68:1541–47; discussion 1547 doi:10.1227/NEU.0b013e31820edd46 pmid:21311378
    CrossRefPubMed
  30. 30.↵
    1. Feng L,
    2. Fitzsimmons BF,
    3. Young WL, et al
    . Intraarterially administered verapamil as adjunct therapy for cerebral vasospasm: safety and 2-year experience. AJNR Am J Neuroradiol 2002;23:1284–90 pmid:12223366
    Abstract/FREE Full Text
  31. 31.↵
    1. Keuskamp J,
    2. Murali R,
    3. Chao KH
    . High-dose intraarterial verapamil in the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg 2008;108:458–63 doi:10.3171/JNS/2008/108/3/0458 pmid:18312091
    CrossRefPubMed
  32. 32.↵
    1. Rosenwasser RH,
    2. Armonda RA,
    3. Thomas JE, et al
    . Therapeutic modalities for the management of cerebral vasospasm: timing of endovascular options. Neurosurgery 1999;44:975–79; discussion 979–80 doi:10.1097/00006123-199905000-00022 pmid:10232530
    CrossRefPubMed
  33. 33.↵
    1. Khatri R,
    2. Memon MZ,
    3. Zacharatos H, et al
    . Impact of percutaneous transluminal angioplasty for treatment of cerebral vasospasm on subarachnoid hemorrhage patient outcomes. Neurocrit Care 2011;15:28–33 doi:10.1007/s12028-010-9499-y pmid:21360234
    CrossRefPubMed
  34. 34.↵
    1. Pandey AS,
    2. Elias AE,
    3. Chaudhary N, et al
    . Endovascular treatment of cerebral vasospasm: vasodilators and angioplasty. Neuroimaging Clin N Am 2013;23:593–604 doi:10.1016/j.nic.2013.03.008 pmid:24156852
    CrossRefPubMed
  35. 35.↵
    1. Rahme R,
    2. Jimenez L,
    3. Pyne-Geithman GJ, et al
    . Endovascular management of posthemorrhagic cerebral vasospasm: indications, technical nuances, and results. Acta Neurochir Suppl 2013;115:107–12 doi:10.1007/978-3-7091-1192-5_23 pmid:22890655
    CrossRefPubMed
  36. 36.↵
    1. Hui C,
    2. Lau KP
    . Efficacy of intra-arterial nimodipine in the treatment of cerebral vasospasm complicating subarachnoid haemorrhage. Clin Radiol 2005;60:1030–36 doi:10.1016/j.crad.2005.04.004 pmid:16124986
    CrossRefPubMed
  37. 37.↵
    1. Firat MM,
    2. Gelebek V,
    3. Orer HS, et al
    . Selective intraarterial nimodipine treatment in an experimental subarachnoid hemorrhage model. AJNR Am J Neuroradiol 2005;26:1357–62 pmid:15956497
    Abstract/FREE Full Text
  38. 38.↵
    1. Hoh BL,
    2. Ogilvy CS
    . Endovascular treatment of cerebral vasospasm: transluminal balloon angioplasty, intra-arterial papaverine, and intra-arterial nicardipine. Neurosurg Clin N Am 2005;16:501–16, vi pmid:15990041
    CrossRefPubMed
  39. 39.↵
    1. McDougall CG,
    2. Spetzler RF,
    3. Zabramski JM, et al
    . The Barrow Ruptured Aneurysm Trial. J Neurosurg 2012;116:135–44 doi:10.3171/2011.8.JNS101767 pmid:22054213
    CrossRefPubMed
  40. 40.↵
    1. Spetzler RF,
    2. McDougall CG,
    3. Albuquerque FC, et al
    . The Barrow Ruptured Aneurysm Trial: 3-year results. J Neurosurg 2013;119:146–57 doi:10.3171/2013.3.JNS12683 pmid:23621600
    CrossRefPubMed
  41. 41.↵
    1. Spetzler RF,
    2. McDougall CG,
    3. Zabramski JM, et al
    . The Barrow Ruptured Aneurysm Trial: 6-year results. J Neurosurg 2015;123:609–17 doi:10.3171/2014.9.JNS141749 pmid:26115467
    CrossRefPubMed
  42. 42.↵
    1. Molyneux A,
    2. Kerr R,
    3. Stratton I, et al
    ; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet 2002;360:1267–74 doi:10.1016/S0140-6736(02)11314-6 pmid:12414200
    CrossRefPubMed
  43. 43.↵
    1. Molyneux AJ,
    2. Kerr RS,
    3. Birks J, et al
    ; ISAT Collaborators. Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT): long-term follow-up. Lancet Neurol 2009;8:427–33 doi:10.1016/S1474-4422(09)70080-8 pmid:19329361
    CrossRefPubMed
  44. 44.↵
    1. Molyneux AJ,
    2. Kerr RS,
    3. Yu LM, et al
    ; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet 2005;366:809–17 doi:10.1016/S0140-6736(05)67214-5 pmid:16139655
    CrossRefPubMed
  45. 45.↵
    1. Darsaut TE,
    2. Jack AS,
    3. Kerr RS, et al
    . International Subarachnoid Aneurysm Trial-ISAT, Part II: study protocol for a randomized controlled trial. Trials 2013;14:156 doi:10.1186/1745-6215-14-156 pmid:23714335
    CrossRefPubMed
  46. 46.↵
    1. Pegoli M,
    2. Mandrekar J,
    3. Rabinstein AA, et al
    . Predictors of excellent functional outcome in aneurysmal subarachnoid hemorrhage. J Neurosurg 2015;122:414–18 doi:10.3171/2014.10.JNS14290 pmid:25495745
    CrossRefPubMed
  47. 47.↵
    1. Hänggi D,
    2. Etminan N,
    3. Macdonald RL, et al
    . NEWTON: Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage. Neurocrit Care 2015;23:274–84 doi:10.1007/s12028-015-0112-2 pmid:25678453
    CrossRefPubMed
  48. 48.↵
    1. Taufique Z,
    2. May T,
    3. Meyers E, et al
    . Predictors of poor quality of life 1 year after subarachnoid hemorrhage. Neurosurgery 2016;78:256–56 doi:10.1227/NEU.000000000000104284 pmid:26421590
    CrossRefPubMed
  49. 49.↵
    1. Dodel R,
    2. Winter Y,
    3. Ringel F, et al
    . Cost of illness in subarachnoid hemorrhage: a German longitudinal study. Stroke 2010;41:2918–23 doi:10.1161/STROKEAHA.110.586826 pmid:21071720
    Abstract/FREE Full Text
  50. 50.↵
    1. Sehba FA,
    2. Hou J,
    3. Pluta RM, et al
    . The importance of early brain injury after subarachnoid hemorrhage. Prog Neurobiol 2012;97:14–37 doi:10.1016/j.pneurobio.2012.02.003 pmid:22414893
    CrossRefPubMed
  51. 51.↵
    1. Fergusen S,
    2. Macdonald RL
    . Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 2007;60:658–67; discussion 667 pmid:17415202
    PubMed
  52. 52.↵
    1. Rosengart AJ,
    2. Huo JD,
    3. Tolentino J, et al
    . Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. J Neurosurg 2007;107:253–60 doi:10.3171/JNS-07/08/0253 pmid:17695377
    CrossRefPubMed
  53. 53.↵
    1. Bederson JB,
    2. Connolly ES Jr.,
    3. Batjer HH, et al
    ; American Heart Association. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 2009;40:994–1025 doi:10.1161/STROKEAHA.108.191395 pmid:19164800
    FREE Full Text
  54. 54.↵
    1. Dorhout Mees SM,
    2. Rinkel GJ,
    3. Feigin VL, et al
    . Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007:CD000277 pmid:17636626
  55. 55.↵
    1. Rabinstein AA,
    2. Lanzino G,
    3. Wijdicks EF
    . Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage. Lancet Neurol 2010;9:504–19 doi:10.1016/S1474-4422(10)70087-9 pmid:20398858
    CrossRefPubMed
  56. 56.↵
    1. Budohoski KP,
    2. Czosnyka M,
    3. Kirkpatrick PJ, et al
    . Clinical relevance of cerebral autoregulation following subarachnoid haemorrhage. Nat Rev Neurol 2013;9:152–63 doi:10.1038/nrneurol.2013.11 pmid:23419369
    CrossRefPubMed
  • Received April 21, 2016.
  • Accepted after revision October 11, 2016.
  • © 2017 by American Journal of Neuroradiology
View Abstract
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 38 (3)
American Journal of Neuroradiology
Vol. 38, Issue 3
1 Mar 2017
  • Table of Contents
  • Index by author
  • Complete Issue (PDF)
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Feasibility and Safety of Repeat Instant Endovascular Interventions in Patients with Refractory Cerebral Vasospasms
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cite this article
L. Andereggen, J. Beck, W.J. Z'Graggen, G. Schroth, R.H. Andres, M. Murek, M. Haenggi, M. Reinert, A. Raabe, J. Gralla
Feasibility and Safety of Repeat Instant Endovascular Interventions in Patients with Refractory Cerebral Vasospasms
American Journal of Neuroradiology Mar 2017, 38 (3) 561-567; DOI: 10.3174/ajnr.A5024

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
0 Responses
Respond to this article
Share
Bookmark this article
Feasibility and Safety of Repeat Instant Endovascular Interventions in Patients with Refractory Cerebral Vasospasms
L. Andereggen, J. Beck, W.J. Z'Graggen, G. Schroth, R.H. Andres, M. Murek, M. Haenggi, M. Reinert, A. Raabe, J. Gralla
American Journal of Neuroradiology Mar 2017, 38 (3) 561-567; DOI: 10.3174/ajnr.A5024
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • ABBREVIATIONS:
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Responses
  • References
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Stent Angioplasty for the Treatment of Cerebral Vasospasm: A Systematic Review and Meta-Analysis
  • Risk Factors for Unfavorable Functional Outcome after Endovascular Treatment of Cerebral Vasospasm following Aneurysmal Subarachnoid Hemorrhage
  • Distal cerebral vasospasm treatment following aneurysmal subarachnoid hemorrhage using the Comaneci device: technical feasibility and single-center preliminary results
  • Levosimendan as a therapeutic strategy to prevent neuroinflammation after aneurysmal subarachnoid hemorrhage?
  • Reliability of the Diagnosis of Cerebral Vasospasm Using Catheter Cerebral Angiography: A Systematic Review and Inter- and Intraobserver Study
  • Distal Balloon Angioplasty of Cerebral Vasospasm Decreases the Risk of Delayed Cerebral Infarction
  • Crossref (33)
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • A Review of the Management of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage
    Kenny Li, Christen D. Barras, Ronil V. Chandra, Hong K. Kok, Julian T. Maingard, Nicole S. Carter, Jeremy H. Russell, Leon Lai, Mark Brooks, Hamed Asadi
    World Neurosurgery 2019 126
  • Endovascular Rescue Treatment for Delayed Cerebral Ischemia After Subarachnoid Hemorrhage Is Safe and Effective
    Miriam Weiss, Catharina Conzen, Marguerite Mueller, Martin Wiesmann, Hans Clusmann, Walid Albanna, Gerrit Alexander Schubert
    Frontiers in Neurology 2019 10
  • Distal Balloon Angioplasty of Cerebral Vasospasm Decreases the Risk of Delayed Cerebral Infarction
    M.-A. Labeyrie, S. Gaugain, G. Boulouis, A. Zetchi, J. Brami, J.-P. Saint-Maurice, V. Civelli, S. Froelich, E. Houdart
    American Journal of Neuroradiology 2019 40 8
  • Reliability of the Diagnosis of Cerebral Vasospasm Using Catheter Cerebral Angiography: A Systematic Review and Inter- and Intraobserver Study
    T.E. Darsaut, C. Derksen, B. Farzin, M.B. Keough, R. Fahed, W. Boisseau, L. Letourneau-Guillon, A.-C. Januel, A. Weill, D. Roy, T.N. Nguyen, S. Finitsis, J.-C. Gentric, D. Volders, A. Carlson, M.M. Chow, C. O’Kelly, J.L. Rempel, R.A. Ashforth, M. Chagnon, J. Zehr, J.M. Findlay, G. Gevry, J. Raymond
    American Journal of Neuroradiology 2021 42 3
  • The Role of Sartans in the Treatment of Stroke and Subarachnoid Hemorrhage: A Narrative Review of Preclinical and Clinical Studies
    Stefan Wanderer, Basil E. Grüter, Fabio Strange, Sivani Sivanrupan, Stefano Di Santo, Hans Rudolf Widmer, Javier Fandino, Serge Marbacher, Lukas Andereggen
    Brain Sciences 2020 10 3
  • The Impact of Intra-Arterial Papaverine-Hydrochloride on Cerebral Metabolism and Oxygenation for Treatment of Delayed-Onset Post-Subarachnoid Hemorrhage Vasospasm
    Arthur Hosmann, Wei-te Wang, Philippe Dodier, Gerhard Bavinzski, Adrian Engel, Johannes Herta, Walter Plöchl, Andrea Reinprecht, Andreas Gruber
    Neurosurgery 2020 87 4
  • Distal cerebral vasospasm treatment following aneurysmal subarachnoid hemorrhage using the Comaneci device: technical feasibility and single-center preliminary results
    Louis Thiery, Xavier Carle, Benoit Testud, Gregoire Boulouis, Paul Habert, Farouk Tradi, Anthony Reyre, Pierre Lehmann, Philippe Dory-Lautrec, Jan-Patrick Stellmann, Nadine Girard, Herve Brunel, Jean-Francois Hak
    Journal of NeuroInterventional Surgery 2023 15 4
  • Intraarterial Nimodipine Versus Induced Hypertension for Delayed Cerebral Ischemia: A Modified Treatment Protocol
    Miriam Weiss, Walid Albanna, Catharina Conzen-Dilger, Nick Kastenholz, Katharina Seyfried, Hani Ridwan, Martin Wiesmann, Michael Veldeman, Tobias Philip Schmidt, Murad Megjhani, Henna Schulze-Steinen, Hans Clusmann, Marinus Johannes Hermanus Aries, Soojin Park, Gerrit Alexander Schubert
    Stroke 2022 53 8
  • Effect of intraoperative infusion of dexmedetomidine on postoperative recovery in patients undergoing endovascular interventional therapies: A prospective, randomized, controlled trial
    Chunguang Ren, Huiying Xu, Guangjun Xu, Lei Liu, Guoying Liu, Zongwang Zhang, Jun-Li Cao
    Brain and Behavior 2019 9 7
  • Repeated Endovascular Treatments in Patients with Recurrent Cerebral Vasospasms After Subarachnoid Hemorrhage: A Worthwhile Strategy?
    Claudia Ditz, Alexander Neumann, Jann Wojak, Emma Smith, Jan Gliemroth, Volker Tronnier, Jan Küchler
    World Neurosurgery 2018 112

More in this TOC Section

  • Factors Associated with Major Re-Recanalization following Second Coiling for Recanalized Aneurysms: A Multicenter Experience over 20 Years during Long-Term Follow-up
  • A Key Factor Shapes LS-DAVFs EVT Outcome
  • Optimizing Voxel Size in 3D Rotational Angiography
Show more NEUROINTERVENTION

Similar Articles

Advertisement

Indexed Content

  • Current Issue
  • Accepted Manuscripts
  • Article Preview
  • Past Issues
  • Editorials
  • Editor's Choice
  • Fellows' Journal Club
  • Letters to the Editor
  • Video Articles

Cases

  • Case Collection
  • Archive - Case of the Week
  • Archive - Case of the Month
  • Archive - Classic Case

More from AJNR

  • Trainee Corner
  • Imaging Protocols
  • MRI Safety Corner

Multimedia

  • AJNR Podcasts
  • AJNR Scantastics

Resources

  • Turnaround Time
  • Submit a Manuscript
  • Submit a Video Article
  • Submit an eLetter to the Editor/Response
  • Manuscript Submission Guidelines
  • Statistical Tips
  • Fast Publishing of Accepted Manuscripts
  • Graphical Abstract Preparation
  • Imaging Protocol Submission
  • Evidence-Based Medicine Level Guide
  • Publishing Checklists
  • Author Policies
  • Become a Reviewer/Academy of Reviewers
  • News and Updates

About Us

  • About AJNR
  • Editorial Board
  • Editorial Board Alumni
  • Alerts
  • Permissions
  • Not an AJNR Subscriber? Join Now
  • Advertise with Us
  • Librarian Resources
  • Feedback
  • Terms and Conditions
  • AJNR Editorial Board Alumni

American Society of Neuroradiology

  • Not an ASNR Member? Join Now

© 2025 by the American Society of Neuroradiology All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire